Supriya Lifescience
758.65
-3.10(-0.41%)
Market Cap₹6,105.83 Cr
PE Ratio34.08
IndustryHealthcare
Company Performance:
1D-0.41%
1M+1.18%
6M+4.97%
1Y+0.17%
5Y+94.10%
View Company Insightsright
More news about Supriya Lifescience
29May 25
Supriya Lifescience Unveils Ambitious Growth Strategy, Targets ₹1,000 Crore Revenue by FY27
Supriya Lifescience announced robust growth plans during a recent conference call. The company's formulation facility is expected to generate ₹450-500 crore in revenue. They maintained a 20% annual revenue growth guidance with EBITDA margins of 33-35%. A mid-term goal of ₹1,000 crore revenue by FY2027 was set. The company anticipates stronger volume growth over the next two years, driven by full capacity utilization of Module E by FY27 and launch of new products with significant global volume potential.
27May 25
Supriya Lifescience Reports Strong Q4 Results, Announces Dividend
Supriya Lifescience Ltd. has released its Q4 financial results, showing significant year-over-year growth. Revenue increased by 16.46% to ₹1,840.00 million, EBITDA rose by 21.80% to ₹676.00 million, and net profit surged by 36.59% to ₹504.00 million. The company's EBITDA margin expanded to 36.72% from 35.09% in the previous year. Quarter-on-quarter growth was also notable, with net profit increasing by 7.69%. The board has recommended a dividend of ₹1.00 per equity share.
Supriya Lifescience
758.65
-3.10
(-0.41%)
1 Year Returns:+0.17%
Industry Peers
Sun Pharmaceutical
1,826.00
(+0.87%)
Divis Laboratories
6,458.50
(-0.49%)
Torrent Pharmaceuticals
3,721.80
(-0.23%)
Cipla
1,530.10
(+0.32%)
Dr Reddys Laboratories
1,253.50
(+0.34%)
Lupin
2,080.30
(+0.43%)
Zydus Life Science
940.90
(+0.39%)
Mankind Pharma
2,250.80
(+0.07%)
Aurobindo Pharma
1,233.40
(-0.19%)
Alkem Laboratories
5,696.00
(+0.17%)